AU2021341452A1 - Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities - Google Patents

Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities Download PDF

Info

Publication number
AU2021341452A1
AU2021341452A1 AU2021341452A AU2021341452A AU2021341452A1 AU 2021341452 A1 AU2021341452 A1 AU 2021341452A1 AU 2021341452 A AU2021341452 A AU 2021341452A AU 2021341452 A AU2021341452 A AU 2021341452A AU 2021341452 A1 AU2021341452 A1 AU 2021341452A1
Authority
AU
Australia
Prior art keywords
cbdv
seizures
preparation
motor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021341452A
Other languages
English (en)
Inventor
Kevin James CRAIG
John Anthony LAWSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Research UK Ltd
Original Assignee
Jazz Pharmaceuticals Research UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Research UK Ltd filed Critical Jazz Pharmaceuticals Research UK Ltd
Publication of AU2021341452A1 publication Critical patent/AU2021341452A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021341452A 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities Pending AU2021341452A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2014250.1A GB202014250D0 (en) 2020-09-10 2020-09-10 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2014250.1 2020-09-10
PCT/EP2021/074661 WO2022053486A1 (en) 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Publications (1)

Publication Number Publication Date
AU2021341452A1 true AU2021341452A1 (en) 2023-03-23

Family

ID=73149611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021341452A Pending AU2021341452A1 (en) 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Country Status (10)

Country Link
US (1) US20230346809A1 (enExample)
EP (1) EP4210685B1 (enExample)
JP (1) JP7817990B2 (enExample)
KR (1) KR20230066417A (enExample)
CN (1) CN116234580A (enExample)
AU (1) AU2021341452A1 (enExample)
CA (1) CA3191266A1 (enExample)
GB (2) GB202014250D0 (enExample)
MX (1) MX2023002837A (enExample)
WO (1) WO2022053486A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487183B (en) * 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
GB2569961B (en) * 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2588458A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Cannabidivarin preparations

Also Published As

Publication number Publication date
JP2023540614A (ja) 2023-09-25
GB202112440D0 (en) 2021-10-13
KR20230066417A (ko) 2023-05-15
MX2023002837A (es) 2023-03-17
JP7817990B2 (ja) 2026-02-19
CA3191266A1 (en) 2022-03-17
EP4210685B1 (en) 2025-11-26
GB2599492A (en) 2022-04-06
US20230346809A1 (en) 2023-11-02
GB202014250D0 (en) 2020-10-28
WO2022053486A1 (en) 2022-03-17
CN116234580A (zh) 2023-06-06
EP4210685A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
EP4210685B1 (en) Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4181890B1 (en) Use of cannabidiol in the treatment of seizures associated with rett syndrome
EP4181891B1 (en) Use of cannabidiol in the treatment of absence seizures associated with rare epilepsy syndromes related to brain injury
WO2022017942A1 (en) Use of cannabidiol in the treatment of seizures associated with mutations in the syngap1 gene
WO2022017935A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017945A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017947A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4181902A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4259112A1 (en) Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes in patients taking brivaracetam
CA2963208C (en) USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
WO2022017944A1 (en) Use of cannabidiol in the treatment of seizures associated with bilateral cerebral dysgenesis
WO2022017957A1 (en) Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
WO2022017915A1 (en) Cannabidiol for use in the treatment of seizures associated with brain damage
WO2022017930A1 (en) Use of cannabidiol in the treatment of seizures associated with jeavon's syndrome
WO2022017936A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017929A1 (en) Use of cannabidiol in the treatment of seizures associated lissencephaly
WO2022017958A1 (en) Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017917A1 (en) Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017961A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597278A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597305A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO JAZZ PHARMACEUTICALS RESEARCH UK LIMITED